ProCE Banner Activity

NEMO: Binimetinib Shows Promising Activity in NRAS-Mutant Cutaneous Melanoma

Slideset Download
Conference Coverage
Binimetinib significantly improved PFS and response rates in NRAS-mutant melanoma, particularly in patients who received prior immunotherapy.

Released: June 10, 2016

Expiration: June 09, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals